NEW YORK (GenomeWeb News) – A substantial investor in Illumina's stock is suing the company alleging breach of fiduciary duty in connection with Roche's efforts to buy the San Diego-based company and its efforts to fend off that approach.

In a lawsuit filed with the US District Court, Southern District of New York this week, the plaintiffs, Vista Capital Management, seeks damages of more than $10 million.

Based in Geneva, Vista is a privately held financial services firm that owned more than 300,000 shares of Illumina stock during the periods covered by its lawsuit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.